Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04821297 · ClinicalTrials.gov registry record · NA
Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results
A NA study of Cervical Carcinoma, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04821297: Completed NA study of Cervical Carcinoma, sponsored by Thomas Jefferson University.
NCT04821297 is a NA study of Cervical Carcinoma that has completed, run by Thomas Jefferson University. The registered enrollment target is 30 participants, below the 534-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04821297, a NA study of Cervical Carcinoma, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates the feasibility of a linguistically-tailored mobile intervention, called CervixChat in improving the follow-up of patients with abnormal Papanicolaou (pap) test results. A text messaging program, such as CervixChat may support patients who need a colposcopy.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Interview
- OTHER Health Promotion and Education
Study Locations (1)
Pennsylvania
- Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-09-10 |
| Phase | NA |
What the finished NCT04821297 record still lists
NCT04821297 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 534-participant average among 25 other Cervical Carcinoma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Cervical Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.
NCT04821297 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04821297 about?
NCT04821297 is a clinical study titled "Linguistically-Tailored Mobile Intervention for the Improvement of Follow Up for Abnormal Pap Test Results". This clinical trial evaluates the feasibility of a linguistically-tailored mobile intervention, called CervixChat in improving the follow-up of patients with abnormal Papanicolaou (pap) test results. A text messaging program, such as CervixChat may support patients who need a colposcopy.
What is the current status of trial NCT04821297?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-02-18. Estimated completion is 2021-09-10.
What conditions does trial NCT04821297 study?
This clinical trial studies the following conditions: Cervical Carcinoma.
What interventions are being tested in trial NCT04821297?
The interventions under investigation include: Survey Administration (OTHER), Interview (OTHER), Health Promotion and Education (OTHER).
Who is sponsoring clinical trial NCT04821297?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04821297 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04821297's enrollment target sits among peer trials
30 20th of 25 higher than 5 of 25 other Cervical Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
RECRUITING · NA
-
The Ohio State University (OSU) SCREEN Community Program
RECRUITING · NA
-
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
ACTIVE NOT RECRUITING · NA
-
I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI